IMMH001
Modify Date: 2024-01-09 19:11:58
IMMH001 structure
|
Common Name | IMMH001 | ||
|---|---|---|---|---|
| CAS Number | 1418093-75-0 | Molecular Weight | 380.48 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C23H28N2O3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of IMMH001IMMH001, also called SYL930, is an orally active, potent and selective S1P1 (sphingosine-1-phosphate receptor 1) agonist. IMMH001 decreased levels of both chemokines and proinflammatory cytokines, including IL-1β, IL-5, IL-18, IP10, CCL3, and CCL5. IMMH001 can be used for rheumatoid arthritis (RA) research[1][2]. |
| Name | IMMH001 |
|---|
| Description | IMMH001, also called SYL930, is an orally active, potent and selective S1P1 (sphingosine-1-phosphate receptor 1) agonist. IMMH001 decreased levels of both chemokines and proinflammatory cytokines, including IL-1β, IL-5, IL-18, IP10, CCL3, and CCL5. IMMH001 can be used for rheumatoid arthritis (RA) research[1][2]. |
|---|---|
| Related Catalog | |
| Target |
S1PR1 |
| In Vivo | IMMH001 is converted to the active form, its monophosphate ester (S)-IMMH001-P, by sphingosine kinase 1 (SphK1) and sphingosine kinase 2 (SphK2) in vivo[1]. IMMH001 suppresses both Th1 cell (IL-1β, IL-18, and IP10) and Th2 cell (IL-5)-mediated disease reactions in damaged joints[2]. IMMH001 (0.3-2.4 mg/kg, Orally; twice a week, for 28 days, AA rats; for 30 days, CIA rats) relieves the damage of AA (adjuvant-induced arthritis) and CIA (collagen-induced arthritis) rats’ joints[2]. |
| References |
| Molecular Formula | C23H28N2O3 |
|---|---|
| Molecular Weight | 380.48 |